GemPharmatech (SH:688046) Zheng Quan Shi Bao Wang·2025-09-08 09:00Group 1 - Jiangsu Jicui Yaokang Biotechnology Co., Ltd. (Yaokang Bio) and Shanghai Yinos Biotech Co., Ltd. (Yinos) have signed a strategic cooperation agreement to enhance collaboration in the field of non-clinical safety evaluation and model development [1] - Yaokang Bio is a leading company in the domestic model animal sector, focusing on non-clinical safety evaluation and has accumulated extensive data on mouse models for carcinogenic evaluation, which exhibit a high response rate to positive carcinogens [1][2] - Yinos is a top-tier non-clinical safety evaluation institution in China, compliant with Good Laboratory Practice (GLP) standards, possessing comprehensive toxicology research qualifications and international service capabilities [1][2] Group 2 - The collaboration aims to standardize the application of domestically developed non-clinical carcinogenic evaluation mouse models, enhancing their recognition in the industry and promoting their commercialization [2] - Both companies will share experimental data related to tumor incidence, latency, and histopathological characteristics to improve the model's industry acceptance [2] - The partnership will facilitate the large-scale application of these models in innovative drug development enterprises [2] Group 3 - Yaokang Bio will leverage its strengths in model construction and non-GLP pharmacology and toxicology evaluation to provide preliminary drug activity screening and mechanism research services for overseas clients [3] - Yinos will utilize its internationally certified GLP toxicology evaluation qualifications to conduct subsequent pharmacokinetic and safety evaluations [3] - The collaboration aims to create a comprehensive overseas customer service loop, integrating efficacy, pharmacokinetics, and safety evaluation [3] Group 4 - The partnership combines the resource advantages of both companies, facilitating the entry of Yaokang Bio's mouse models into the evaluation supply chain [4] - The collaboration will target key domestic and international clients, establishing a benchmark cooperation model for the biopharmaceutical industry [4] - A global service network will be developed, covering major pharmaceutical markets, promoting the "Chinese model animals + Chinese evaluation services" paradigm [4]